CTOT-45 (Lung Transplantation) - Clinical Trial
Email to Participate
kathleen.lane@duke.edu
What is the Purpose of this Study?
We are doing this study to find out if an investigational drug called tocilizumab (the study drug) will lead to better outcomes after lung transplantation when it is combined with standard anti-rejection medicines.
What is the Condition Being Studied?
Lung Transplantation
Who Can Participate in the Study?
Adults ages 18+ who are on the list to receive a lung transplant.
For more information about who can join this study, please contact the study team at kathleen.lane@duke.edu.
Age Group
Adults
What is Involved?
If choose to join this study, you will:
- Get a random assignment (like a coin flip) to take the study drug or placebo (an inactive substance)
- Take the study drug or placebo once a month for five months after your lung transplant
- Have blood draws
- Have lung biopsy samples collected
- Have information collected from your medical record
- Have study visits for up to 3 years after your lung transplant
Study Details
Full Title
TARGETING INFLAMMATION AND ALLOIMMUNITY IN LUNG TRANSPLANT RECIPIENTS
WITH TOCILIZUMAB (ALL IN LUNG)
Principal Investigator
Lung Transplant Surgeon
Protocol Number
IRB:
PRO00113759
NCT:
NCT06033196
Phase
Phase
II
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Email kathleen.lane@duke.edu